OR WAIT 15 SECS
© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.